{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:23:28Z","timestamp":1779254608370,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>According to real-world data, only up to 20% of patients with atherosclerotic cardiovascular disease (ASCVD) are below the recommended LDL-cholesterol (LDL-C) target of &amp;lt;55\u2005mg\/dL (&amp;lt;1.4\u2005mmol\/L) 1\u20133 months after the index event. Accordingly, improved strategies for initiating lipid-lowering therapy (LLT) are desired to achieve treatment targets required to further reduce future cardiovascular event rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The COR Lipid Registry included patients at very high cardiovascular (CV) risk presenting for percutaneous coronary intervention (PCI) with acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). Coronary artery disease (CAD) patients with an LDL-C level of &amp;gt;130\u2005mg\/dL (equalizing 3.37\u2005mmol\/L) or a non-HDL of 160\u2005mg\/dL (equalizing 4.14\u2005mmol\/L) either LLT-na\u00efve or with suboptimal LLT at index hospitalization were enrolled. Based on lipid levels at baseline, these patients were assumed to need triple LLT to achieve their LDL-C target. Baseline characteristics and lipid parameters of all patients were collected at index hospitalization and two follow-up visits, after 4\u20136 and 8\u201312 weeks, respectively. Initially, in all patients a dual LLT (high-dose, highly effective statin, which means atorvastatin 40\u2005mg or 80\u2005mg and rosuvastatin 20\u2005mg or 40\u2005mg, plus ezetimibe) was initiated during the index hospitalization, before PCSK9 inhibitors or bempedoic acid were added, if LDL-C target levels were not met at control visits. In total, 165 very high-risk patients were included, of which 79 (42.0%) were admitted for CCS and 109 (58%) for ACS, respectively. At Visit 1, 114 (69.1%) patients reached the recommended (ESC\/EAS guidelines 2019) lipid goals (LDL-C of &amp;lt; 55\u2005mg\/dL; equalizing 1.4\u2005mmol\/L; or non-HDL-C of 85\u2005mg\/dL equalizing 2.2\u2005mmol\/&amp;lt;L), while 160 patients (97%) met the target at Visit 2. In ACS patients, 74.3% reached the recommended treatment goal (LDL-C or non-HDL-C) at Visit 1 and 97.3% at Visit 2. In CCS patients, the treatment goal was achieved in 60.8% at Visit 1 and 100% at Visit 2, respectively. In the LLT-na\u00efve group at admission (n = 64), the treatment goal was met in 61.5% of patients at Visit 1 and in 96.9% of patients at Visit 2, while for LLT-pre-treated patients, the respective data were 76.3% and 100%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An optimized LLT strategy for managing a very high CV risk patient cohort undergoing PCI, starting with a dual LLT strategy consisting of a high-dose, highly effective statin plus ezetimibe at the index event followed by addition of a third LL-agent (a PCSK9 inhibitor or bempedoic acid) at follow-up after 4\u20136 weeks if treatment goal was not reached, was highly effective in achieving LDL-C and non-HDL-C goals. Wider adoption of this strategy may help to significantly improve LDL-C target levels in real-world populations in very high-risk CAD patients presenting with ACS or CCS for coronary revascularization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjacc\/zuaf137","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:37:29Z","timestamp":1761568649000},"page":"289-296","source":"Crossref","is-referenced-by-count":1,"title":["The COR Lipid Registry: the effectiveness of the strike early and strike strong strategy in patients with high cardiovascular risk"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-1175","authenticated-orcid":false,"given":"Patrick","family":"Weltler","sequence":"first","affiliation":[{"name":"3rd Medical Department for Cardiology and Intensive Care Medicine, Klinik Ottakring , Montleartsta\u00dfe 37, 1160 Vienna ,","place":["Austria"]},{"name":"Ludwig Boltzmann Institute for Cardiovascular Research , Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul F","family":"Harbich","sequence":"additional","affiliation":[{"name":"3rd Medical Department for Cardiology and Intensive Care Medicine, Klinik Ottakring , Montleartsta\u00dfe 37, 1160 Vienna ,","place":["Austria"]},{"name":"Ludwig Boltzmann Institute for Cardiovascular Research , Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Burger","sequence":"additional","affiliation":[{"name":"3rd Medical Department for Cardiology and Intensive Care Medicine, Klinik Ottakring , Montleartsta\u00dfe 37, 1160 Vienna ,","place":["Austria"]},{"name":"Sigmund Freud University, Faculty of Medicine , Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Dobner","sequence":"additional","affiliation":[{"name":"3rd Medical Department for Cardiology and Intensive Care Medicine, Klinik Ottakring , Montleartsta\u00dfe 37, 1160 Vienna ,","place":["Austria"]},{"name":"Ludwig Boltzmann Institute for Cardiovascular Research , Vienna ,","place":["Austria"]},{"name":"Sigmund Freud University, Faculty of Medicine , Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph C","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"3rd Medical Department for Cardiology and Intensive Care Medicine, Klinik Ottakring , Montleartsta\u00dfe 37, 1160 Vienna ,","place":["Austria"]},{"name":"Sigmund Freud University, Faculty of Medicine , Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Geppert","sequence":"additional","affiliation":[{"name":"3rd Medical Department for Cardiology and Intensive Care Medicine, Klinik Ottakring , Montleartsta\u00dfe 37, 1160 Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-3378","authenticated-orcid":false,"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Cardiovascular Research , Vienna ,","place":["Austria"]},{"name":"Austrian Heart Foundation , Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edita","family":"Pogran","sequence":"additional","affiliation":[{"name":"3rd Medical Department for Cardiology and Intensive Care Medicine, Klinik Ottakring , Montleartsta\u00dfe 37, 1160 Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"2026042812513784700_zuaf137-B1","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks, 1990\u20132022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026042812513784700_zuaf137-B2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"2026042812513784700_zuaf137-B3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026042812513784700_zuaf137-B4","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026042812513784700_zuaf137-B5","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026042812513784700_zuaf137-B6","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026042812513784700_zuaf137-B7","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026042812513784700_zuaf137-B8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026042812513784700_zuaf137-B9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MCA.0000000000001420","article-title":"Lipid-lowering therapy after acute coronary syndromes: a multinational European survey","volume":"36","author":"Tsaban","year":"2025","journal-title":"Coron Artery Dis"},{"key":"2026042812513784700_zuaf137-B10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ehjcvp\/pvaf004","article-title":"Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction","volume":"11","author":"Patti","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026042812513784700_zuaf137-B11","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae209","article-title":"Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry","volume":"31","author":"Gargiulo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026042812513784700_zuaf137-B12","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026042812513784700_zuaf137-B13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation"},{"key":"2026042812513784700_zuaf137-B14","first-page":"939","article-title":"Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular pharmacotherapy","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026042812513784700_zuaf137-B15","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"2026042812513784700_zuaf137-B16","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026042812513784700_zuaf137-B17","doi-asserted-by":"crossref","first-page":"118581","DOI":"10.1016\/j.atherosclerosis.2024.118581","article-title":"Very short-term effects of a single dose of a proprotein convertase subtilisin\/kexin 9 inhibitor before percutaneous coronary intervention: a single-arm study","volume":"399","author":"Kataoka","year":"2024","journal-title":"Atherosclerosis"},{"key":"2026042812513784700_zuaf137-B18"},{"key":"2026042812513784700_zuaf137-B19"},{"key":"2026042812513784700_zuaf137-B20"},{"key":"2026042812513784700_zuaf137-B21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ehjqcco\/qcab039","article-title":"The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry)","volume":"7","author":"B\u00e4ck","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026042812513784700_zuaf137-B22","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","article-title":"Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry","volume":"85","author":"Leosdottir","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal: Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/advance-article-pdf\/doi\/10.1093\/ehjacc\/zuaf137\/65006532\/zuaf137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/4\/289\/65006532\/zuaf137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/4\/289\/65006532\/zuaf137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:51:45Z","timestamp":1777395105000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/15\/4\/289\/8305357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuaf137","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,10,28]]}}}